Lv11
40 积分 2022-05-24 加入
Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma
2小时前
待确认
Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma
2小时前
已关闭
Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma
1个月前
已关闭
Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma
1个月前
已关闭
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma
1个月前
已完结
Breakthrough invasive fungal infection among patients with haematologic malignancies: A national, prospective, and multicentre study
5个月前
已完结
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
6个月前
已完结
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
6个月前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
6个月前
已完结
Monoclonal Gammopathy of Renal Significance
6个月前
已完结
皖公网安备34019202002308
